GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Livzon Pharmaceutical Group Inc (SZSE:000513) » Definitions » Debt-to-Revenue

Livzon Pharmaceutical Group (SZSE:000513) Debt-to-Revenue : 0.28 (As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Livzon Pharmaceutical Group Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Livzon Pharmaceutical Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥2,700 Mil. Livzon Pharmaceutical Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥864 Mil. Livzon Pharmaceutical Group's annualized Revenue for the quarter that ended in Mar. 2024 was ¥12,971 Mil. Livzon Pharmaceutical Group's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.27.


Livzon Pharmaceutical Group Debt-to-Revenue Historical Data

The historical data trend for Livzon Pharmaceutical Group's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Livzon Pharmaceutical Group Debt-to-Revenue Chart

Livzon Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.18 0.22 0.29 0.33

Livzon Pharmaceutical Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.33 0.34 0.37 0.28

Competitive Comparison of Livzon Pharmaceutical Group's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Livzon Pharmaceutical Group's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Livzon Pharmaceutical Group's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Livzon Pharmaceutical Group's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Livzon Pharmaceutical Group's Debt-to-Revenue falls into.



Livzon Pharmaceutical Group Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Livzon Pharmaceutical Group's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2519.689 + 1621.804) / 12430.038
=0.33

Livzon Pharmaceutical Group's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2699.875 + 864.402) / 12971.26
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Livzon Pharmaceutical Group Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Livzon Pharmaceutical Group's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Livzon Pharmaceutical Group (SZSE:000513) Business Description

Traded in Other Exchanges
Address
38 Chuangye North Road, Headquarters Building, Jinwan District, Guangdong Province, Zhuhai, CHN, 519090
Livzon Pharmaceutical Group Inc is engaged in China's healthcare sector. As a pharmaceutical manufacturer, the company's portfolio comprises Western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. Its drug address serious conditions such as gastrointestinal, cardiovascular, anti-infectious, antimicrobial, antineoplastic, hemopoietic system, and other conditions. It distributes its products within domestic markets and to overseas markets. It operates in a single reportable segment which is pharmaceutical manufacturing.

Livzon Pharmaceutical Group (SZSE:000513) Headlines

No Headlines